Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
RECRUITING
Total Enrollment
30 participants
Study Classification
OBSERVATIONAL
Study Start Date
2025-01-01
Study Completion Date
2030-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
In resource-constrained settings such as Malawi, survival rates for pediatric acute myeloid leukemia (AML) are dismally low compared to high-resource environments. This disparity highlights the urgent need for feasible treatment protocols tailored to the realities of these regions where most children with cancer are treated. In 2023, after reviewing favorable clinical trials results in other resource-limited settings, the Kamuzu Central Hospital (KCH) pediatric cancer unit adopted an evidence-based intensity-adapted clinical practice guideline (CPG) developed by the International Society of Paediatric Oncology (SIOP) as its standard of care for the treatment of pediatric AML, aiming to balance curative intent with manageable toxicity. The current study is a prospective evaluation of outcomes of standard of care in Malawi using the SIOP CPG in a real-world setting.
The LEAP study aims to assess the implementation of the SIOP AML guidelines at KCH in an effort to continually improve outcomes in Malawi. The study is an observational-implementation design with a composite effectiveness-implementation outcome called Implementation Success. Implementation Success combines feasibility, the ability of patients to complete all aspects of the CPG, with effectiveness, the ability to maintain historical rates of complete remission of 40% at the treatment center.
This prospective cohort study will enroll children under 18 years diagnosed with de novo AML at KCH. Implementation Success will be the primary endpoint, with secondary endpoints including CPG fidelity, long-term survival, adverse events, and hematologic recovery times. Patient-reported outcomes will also be collected to assess the impact of treatment on quality of life.
This will be the first prospective study of pediatric AML in sub-Saharan Africa, providing critical data on the management of AML in low-resource settings. By assessing the implementation of a context-adapted CPG, the study will contribute to the global effort to improve pediatric AML outcomes in resource-constrained environments. The findings will serve to guide practitioners in Malawi and similar settings, and the data generated will be invaluable for future clinical decisions and CPG development.
The LEAP study aims to assess the implementation of the SIOP AML guidelines at KCH in an effort to continually improve outcomes in Malawi. The study is an observational-implementation design with a composite effectiveness-implementation outcome called Implementation Success. Implementation Success combines feasibility, the ability of patients to complete all aspects of the CPG, with effectiveness, the ability to maintain historical rates of complete remission of 40% at the treatment center.
This prospective cohort study will enroll children under 18 years diagnosed with de novo AML at KCH. Implementation Success will be the primary endpoint, with secondary endpoints including CPG fidelity, long-term survival, adverse events, and hematologic recovery times. Patient-reported outcomes will also be collected to assess the impact of treatment on quality of life.
This will be the first prospective study of pediatric AML in sub-Saharan Africa, providing critical data on the management of AML in low-resource settings. By assessing the implementation of a context-adapted CPG, the study will contribute to the global effort to improve pediatric AML outcomes in resource-constrained environments. The findings will serve to guide practitioners in Malawi and similar settings, and the data generated will be invaluable for future clinical decisions and CPG development.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Individualized Treatment of Pediatric R/R AML Based on Transcriptomic Profile and in Vitro Drug Sensitivity Test
NCT06233526
Acute Myeloid Leukemia in Children
RECRUITING
NA
Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma
NCT01190930
Acute Lymphoblastic Leukemia
Adult B Lymphoblastic Lymphoma
Ann Arbor Stage I B Lymphoblastic Lymphoma
+7 more
ACTIVE_NOT_RECRUITING
PHASE3
Haplo-identical HSCT Versus Chemotherapy for Adult Acute Lymphoblastic Leukemia Patients
NCT02042690
Acute Lymphoblastic Leukemia
COMPLETED
PHASE3
Home Away From Home - Medical Outcomes
NCT02774850
Acute Myeloid Leukemia
Neutropenia
Bacteremia
COMPLETED
Comparison of Consolidation Strategies for Pediatric Patients With Acute Myeloid Leukemia
NCT06211452
AML
Pediatric AML
COMPLETED
PHASE3
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Participants:
* All patients with have de novo AML presenting to Kamuzu Central Hospital (KCH) in Lilongwe, Malawi will be offered enrollment into the study.
* Patients must be \<18 years of age at time of study enrollment.
* Patients must begin treatment according to the 2023 KCH AML therapy CPG.
* All patients at the treating center receiving curative-intent therapy for AML are treated on the 2023 KCH AML standard of care CPG based on the SIOP AML guidelines, independent of participation in research.
* Patients should ideally be consented for data collection within one week of confirmatory diagnosis to ensure highest quality of prospective data collection.
The therapy guideline used at KCH is based upon the published international guidelines for treating pediatric AML in resource-constrained centers published by the International Society of Paediatric Oncology (SIOP). It is currently the standard of care at KCH.
Data Collection Schedule:
All study measurements in this study are routinely captured as part of clinical care. No additional clinical studies will be obtained from patients as a consequence of enrollment onto the LEAP study.
1. On-treatment schedule Patients are routinely admitted inpatient to the pediatric cancer unit at the start of each chemotherapy cycle. Patients remain inpatient according to standard practices of the unit until they no longer require routine blood product transfusions and their absolute neutrophil count is rising. Patients are discharged home for \~1 week prior to returning to start the subsequent cycle, but generally no later than 2 weeks from discharge.
Required Data Items are all routinely obtained as part of standard of care:
* Bone marrow aspirate with morphology +/- trephine biopsy
* Bone marrow flow cytometry OR immunohistochemistry
* Lumbar puncture with cerebrospinal fluid cell count \& morphological evaluation
* Leukemia cytogenetics
* Lanksy score
* Weight, height, MUAC
* History \& physical
* Complete blood count
* Serum electrolytes
* Confirmation of HIV serostatus (standard of care for all pediatric patients in Malawi)
* Chest X-ray
* Echocardiogram
* Adverse event monitoring
* PROMIS-25 parent \& patient questionnaire (additional research-only evaluation)
* REDCap data upload
2. Post-treatment schedule Patients will be followed up by telephone monthly for the first six months off therapy. In-person visits routinely occur at 3 months, 6 months, 9 months, 12 months, 18 months, and 24 months following completion of therapy. They are followed annually thereafter.
Required Data Items:
* History and confirmation of vital status
* Physical exam
* Complete/full blood count
* PROMIS-25 questionnaire
* REDCap data upload
Statistical analysis:
Sample size determination of this study is based on accrual capacity of the study site, not from statistical power. Based on diagnoses over the previous three years at Kamuzu Central Hospital in Malawi, the investigators expect at least 10 de novo cases/year of AML.
Primary Endpoint
CPG Implementation Success will be a composite endpoint comprised of:
1. Feasibility: proportion of patients completing the CPG
2. Effectiveness: proportion of patients in complete remission (CR) by the end of Induction
Implementation will be deemed successful if 1) ≥50% of patients are able to complete the CPG; AND 2) The historical benchmark of end-of-induction complete remission (CR) of 40% is maintained.
Rates of CR (effectiveness outcome) and CPG completion (implementation outcome) will be monitored continuously by the study statistician team using an adaptation of the method of Ivanova and colleagues. This method provides a Pocock-type boundary so that the probability of crossing the boundary is at most 5% when the true rate of the event crosses the acceptable threshold. For the effectiveness threshold of CR, we will use the established historical rate of CR of 40% achieved on the old standard of care for AML in Malawi. The probability of boundary crossing rises to 24%, 68%, and 98% if the CR rate drops to 30%, 20%, and 10%, respectively, with corresponding accruals of N=28, 22, and 14. Similarly, for rate of CPG completion, we will use a threshold of 50%. The probability of boundary crossing rises to 22%, 59%, and 92% if the rate of completion rate drops to 40%, 30%, and 20%, respectively, with corresponding expected accruals of N=27, 22, and 15.
Criteria for completing the CPG are:
1. Completing all required chemotherapy cycles (Induction 1, Induction 2, Consolidation 1, Consolidation 2) and achieving transfusion independence following Consolidation 2 outside of the setting of relapse or bone marrow failure (in which case therapy will be considered complete for the purposes of the study outcome). Note that pre-phase is not required for completion.
2. Completion of Inductions 1 and 2 but not in CR at the end of Induction.
3. Completion of Inductions 1 and 2 having achieved CR by the end of Induction 2 but having had relapse prior to completing Consolidation 2.
4. All patients with early mortality (≤42 days), treatment-related mortality, or treatment abandonment of curative-intent therapy will be considered incomplete.
5. Patients removed from curative-intent therapy due to toxicity will be considered incomplete.
Complete Remission is defined as \<5% myeloblasts on bone marrow evaluation.
Secondary Endpoints
* Event-free, relapse-free, and overall survival at 12 \& 24 months from diagnosis
* Proportion of patients with CTCAE ≥3 adverse events
* Patient-reported outcomes at diagnosis, end of induction, end of therapy, and 6 months post-therapy.
* Cytogenetic characteristics of myeloblasts
* Proportion of discrete treatment and supportive care CPG elements received/completed as prescribed
* All patients with have de novo AML presenting to Kamuzu Central Hospital (KCH) in Lilongwe, Malawi will be offered enrollment into the study.
* Patients must be \<18 years of age at time of study enrollment.
* Patients must begin treatment according to the 2023 KCH AML therapy CPG.
* All patients at the treating center receiving curative-intent therapy for AML are treated on the 2023 KCH AML standard of care CPG based on the SIOP AML guidelines, independent of participation in research.
* Patients should ideally be consented for data collection within one week of confirmatory diagnosis to ensure highest quality of prospective data collection.
The therapy guideline used at KCH is based upon the published international guidelines for treating pediatric AML in resource-constrained centers published by the International Society of Paediatric Oncology (SIOP). It is currently the standard of care at KCH.
Data Collection Schedule:
All study measurements in this study are routinely captured as part of clinical care. No additional clinical studies will be obtained from patients as a consequence of enrollment onto the LEAP study.
1. On-treatment schedule Patients are routinely admitted inpatient to the pediatric cancer unit at the start of each chemotherapy cycle. Patients remain inpatient according to standard practices of the unit until they no longer require routine blood product transfusions and their absolute neutrophil count is rising. Patients are discharged home for \~1 week prior to returning to start the subsequent cycle, but generally no later than 2 weeks from discharge.
Required Data Items are all routinely obtained as part of standard of care:
* Bone marrow aspirate with morphology +/- trephine biopsy
* Bone marrow flow cytometry OR immunohistochemistry
* Lumbar puncture with cerebrospinal fluid cell count \& morphological evaluation
* Leukemia cytogenetics
* Lanksy score
* Weight, height, MUAC
* History \& physical
* Complete blood count
* Serum electrolytes
* Confirmation of HIV serostatus (standard of care for all pediatric patients in Malawi)
* Chest X-ray
* Echocardiogram
* Adverse event monitoring
* PROMIS-25 parent \& patient questionnaire (additional research-only evaluation)
* REDCap data upload
2. Post-treatment schedule Patients will be followed up by telephone monthly for the first six months off therapy. In-person visits routinely occur at 3 months, 6 months, 9 months, 12 months, 18 months, and 24 months following completion of therapy. They are followed annually thereafter.
Required Data Items:
* History and confirmation of vital status
* Physical exam
* Complete/full blood count
* PROMIS-25 questionnaire
* REDCap data upload
Statistical analysis:
Sample size determination of this study is based on accrual capacity of the study site, not from statistical power. Based on diagnoses over the previous three years at Kamuzu Central Hospital in Malawi, the investigators expect at least 10 de novo cases/year of AML.
Primary Endpoint
CPG Implementation Success will be a composite endpoint comprised of:
1. Feasibility: proportion of patients completing the CPG
2. Effectiveness: proportion of patients in complete remission (CR) by the end of Induction
Implementation will be deemed successful if 1) ≥50% of patients are able to complete the CPG; AND 2) The historical benchmark of end-of-induction complete remission (CR) of 40% is maintained.
Rates of CR (effectiveness outcome) and CPG completion (implementation outcome) will be monitored continuously by the study statistician team using an adaptation of the method of Ivanova and colleagues. This method provides a Pocock-type boundary so that the probability of crossing the boundary is at most 5% when the true rate of the event crosses the acceptable threshold. For the effectiveness threshold of CR, we will use the established historical rate of CR of 40% achieved on the old standard of care for AML in Malawi. The probability of boundary crossing rises to 24%, 68%, and 98% if the CR rate drops to 30%, 20%, and 10%, respectively, with corresponding accruals of N=28, 22, and 14. Similarly, for rate of CPG completion, we will use a threshold of 50%. The probability of boundary crossing rises to 22%, 59%, and 92% if the rate of completion rate drops to 40%, 30%, and 20%, respectively, with corresponding expected accruals of N=27, 22, and 15.
Criteria for completing the CPG are:
1. Completing all required chemotherapy cycles (Induction 1, Induction 2, Consolidation 1, Consolidation 2) and achieving transfusion independence following Consolidation 2 outside of the setting of relapse or bone marrow failure (in which case therapy will be considered complete for the purposes of the study outcome). Note that pre-phase is not required for completion.
2. Completion of Inductions 1 and 2 but not in CR at the end of Induction.
3. Completion of Inductions 1 and 2 having achieved CR by the end of Induction 2 but having had relapse prior to completing Consolidation 2.
4. All patients with early mortality (≤42 days), treatment-related mortality, or treatment abandonment of curative-intent therapy will be considered incomplete.
5. Patients removed from curative-intent therapy due to toxicity will be considered incomplete.
Complete Remission is defined as \<5% myeloblasts on bone marrow evaluation.
Secondary Endpoints
* Event-free, relapse-free, and overall survival at 12 \& 24 months from diagnosis
* Proportion of patients with CTCAE ≥3 adverse events
* Patient-reported outcomes at diagnosis, end of induction, end of therapy, and 6 months post-therapy.
* Cytogenetic characteristics of myeloblasts
* Proportion of discrete treatment and supportive care CPG elements received/completed as prescribed
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Acute Myeloid Leukaemia
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Observational Model Type
COHORT
Study Time Perspective
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
All patients with de novo AML
All patients with de novo AML presenting to Kamuzu Central Hospital in Lilongwe, Malawi will be offered enrollment into the study.
Intensity-adapted pediatric acute myeloid treatment guidelines
Intervention Type
OTHER
This is an observational study evaluating the current standard of care AML therapy in Malawi. The therapy guideline used is an adaptation of the International Society of Paediatric Oncology (SIOP) guidelines for pediatric AML in resource-constrained centers published by the International Society of Paediatric Oncology (SIOP). It is currently the standard of care in Malawi for all patients with AML. Receipt of this therapy guideline is independent of participation in research.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Intensity-adapted pediatric acute myeloid treatment guidelines
This is an observational study evaluating the current standard of care AML therapy in Malawi. The therapy guideline used is an adaptation of the International Society of Paediatric Oncology (SIOP) guidelines for pediatric AML in resource-constrained centers published by the International Society of Paediatric Oncology (SIOP). It is currently the standard of care in Malawi for all patients with AML. Receipt of this therapy guideline is independent of participation in research.
Intervention Type
OTHER
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Age Patients must be \<18 years of age at time of study enrollment.
2. Diagnosis
Patients must be diagnosed with de novo AML according to 2022 WHO 5th Edition classification with or without extramedullary disease. Patients must have one of the following:
* Bone marrow myeloblasts ≥20%. In cases of dry taps due to fibrosis, myeloblast percentage can be estimated from a bone marrow biopsy core specimen. Due to unavailable molecular/cytogenetic diagnostics in Malawi, patients with \<20% bone marrow myeloblasts can be included in the study at the discretion of the treating oncologist with rationale documented.
* In cases where a bone marrow evaluation is not safe/feasible, a peripheral blood sample may be used with a documented absolute myeloblast percentage of ≥1000/μL calculated based on a total white blood cell count and percentage circulating blasts.
3. Therapy Patients must begin treatment according to the 2023 KCH AML therapy CPG.
2. Diagnosis
Patients must be diagnosed with de novo AML according to 2022 WHO 5th Edition classification with or without extramedullary disease. Patients must have one of the following:
* Bone marrow myeloblasts ≥20%. In cases of dry taps due to fibrosis, myeloblast percentage can be estimated from a bone marrow biopsy core specimen. Due to unavailable molecular/cytogenetic diagnostics in Malawi, patients with \<20% bone marrow myeloblasts can be included in the study at the discretion of the treating oncologist with rationale documented.
* In cases where a bone marrow evaluation is not safe/feasible, a peripheral blood sample may be used with a documented absolute myeloblast percentage of ≥1000/μL calculated based on a total white blood cell count and percentage circulating blasts.
3. Therapy Patients must begin treatment according to the 2023 KCH AML therapy CPG.
Exclusion Criteria
1. Patients with any of the following conditions or criteria will be excluded from the study:
* Juvenile myelomonocytic leukemia
* Transient myeloproliferative disorder
* Acute promyelocytic leukemia
* Mixed phenotype acute leukemia
* Trisomy 21
* Current pregnancy
* Previous or concurrent malignancy
* Isolated myeloid sarcoma
2. Patients previously treated with antineoplastic therapy with the following exceptions:
* Hydroxyurea
* Corticosteroids
* Intrathecal chemotherapy at diagnosis
* Juvenile myelomonocytic leukemia
* Transient myeloproliferative disorder
* Acute promyelocytic leukemia
* Mixed phenotype acute leukemia
* Trisomy 21
* Current pregnancy
* Previous or concurrent malignancy
* Isolated myeloid sarcoma
2. Patients previously treated with antineoplastic therapy with the following exceptions:
* Hydroxyurea
* Corticosteroids
* Intrathecal chemotherapy at diagnosis
Maximum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
American Society of Hematology
OTHER
Sponsor Role
collaborator
Baylor College of Medicine
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Casey McAtee
Assistant Professor
Responsibility Role
PRINCIPAL_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Casey McAtee, M.D., M.P.H.
Role: PRINCIPAL_INVESTIGATOR
Baylor College of Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Kamuzu Central Hospital
Lilongwe, Lilongwe, Malawi
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
Malawi
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Van Weelderen RE, Klein K, Natawidjaja MD, De Vries R, Kaspers GJ. Outcome of pediatric acute myeloid leukemia (AML) in low- and middle-income countries: a systematic review of the literature. Expert Rev Anticancer Ther. 2021 Jul;21(7):765-780. doi: 10.1080/14737140.2021.1895756. Epub 2021 Mar 29.
Reference Type
BACKGROUND
Roberts N, James S, Delaney M, Fitzmaurice C. The global need and availability of blood products: a modelling study. Lancet Haematol. 2019 Dec;6(12):e606-e615. doi: 10.1016/S2352-3026(19)30200-5. Epub 2019 Oct 17.
Reference Type
BACKGROUND
Tsukimoto I, Tawa A, Horibe K, Tabuchi K, Kigasawa H, Tsuchida M, Yabe H, Nakayama H, Kudo K, Kobayashi R, Hamamoto K, Imaizumi M, Morimoto A, Tsuchiya S, Hanada R. Risk-stratified therapy and the intensive use of cytarabine improves the outcome in childhood acute myeloid leukemia: the AML99 trial from the Japanese Childhood AML Cooperative Study Group. J Clin Oncol. 2009 Aug 20;27(24):4007-13. doi: 10.1200/JCO.2008.18.7948. Epub 2009 Jul 20.
Reference Type
BACKGROUND
Organization, W. H. World Cancer Day 2023: Message of the WHO Regional Director for Africa, Dr. Matshidiso Moeti. https://www.afro.who.int/regional-director/speechesmessages/ world-cancer-day-2023 (2023).
Reference Type
BACKGROUND
Banavali, S. D. et al. PRET: an effective oral protocol for out-patient therapy in patients with acute myeloid leukemia. International Society of Paediatric Oncology Meeting Abstracts (2004).
Reference Type
BACKGROUND
Malani D, Murumagi A, Yadav B, Kontro M, Eldfors S, Kumar A, Karjalainen R, Majumder MM, Ojamies P, Pemovska T, Wennerberg K, Heckman C, Porkka K, Wolf M, Aittokallio T, Kallioniemi O. Enhanced sensitivity to glucocorticoids in cytarabine-resistant AML. Leukemia. 2017 May;31(5):1187-1195. doi: 10.1038/leu.2016.314. Epub 2016 Nov 11.
Reference Type
BACKGROUND
Cooper TM, Absalon MJ, Alonzo TA, Gerbing RB, Leger KJ, Hirsch BA, Pollard J, Razzouk BI, Aplenc R, Kolb EA. Phase I/II Study of CPX-351 Followed by Fludarabine, Cytarabine, and Granulocyte-Colony Stimulating Factor for Children With Relapsed Acute Myeloid Leukemia: A Report From the Children's Oncology Group. J Clin Oncol. 2020 Jul 1;38(19):2170-2177. doi: 10.1200/JCO.19.03306. Epub 2020 May 13.
Reference Type
BACKGROUND
Ivanova A, Qaqish BF, Schell MJ. Continuous toxicity monitoring in phase II trials in oncology. Biometrics. 2005 Jun;61(2):540-5. doi: 10.1111/j.1541-0420.2005.00311.x.
Reference Type
BACKGROUND
Einstein MH, Ndlovu N, Lee J, Stier EA, Kotzen J, Garg M, Whitney K, Lensing SY, Tunmer M, Kadzatsa W, Palefsky J, Krown SE. Cisplatin and radiation therapy in HIV-positive women with locally advanced cervical cancer in sub-Saharan Africa: A phase II study of the AIDS malignancy consortium. Gynecol Oncol. 2019 Apr;153(1):20-25. doi: 10.1016/j.ygyno.2019.01.023. Epub 2019 Feb 15.
Reference Type
BACKGROUND
Health, N. I. of. Common Terminology Criteria for Adverse Events (CTCAE) v. 5.0. httpsctep.cancer.govprotocolDevelopmentelectronicapplicationsctc.htm (2017).
Reference Type
BACKGROUND
Alexander S, Pole JD, Gibson P, Lee M, Hesser T, Chi SN, Dvorak CC, Fisher B, Hasle H, Kanerva J, Moricke A, Phillips B, Raetz E, Rodriguez-Galindo C, Samarasinghe S, Schmiegelow K, Tissing W, Lehrnbecher T, Sung L; International Pediatric Oncology Mortality Classification Group. Classification of treatment-related mortality in children with cancer: a systematic assessment. Lancet Oncol. 2015 Dec;16(16):e604-10. doi: 10.1016/S1470-2045(15)00197-7.
Reference Type
BACKGROUND
Creutzig U, van den Heuvel-Eibrink MM, Gibson B, Dworzak MN, Adachi S, de Bont E, Harbott J, Hasle H, Johnston D, Kinoshita A, Lehrnbecher T, Leverger G, Mejstrikova E, Meshinchi S, Pession A, Raimondi SC, Sung L, Stary J, Zwaan CM, Kaspers GJ, Reinhardt D; AML Committee of the International BFM Study Group. Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel. Blood. 2012 Oct 18;120(16):3187-205. doi: 10.1182/blood-2012-03-362608. Epub 2012 Aug 9.
Reference Type
BACKGROUND
Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, Bejar R, Berti E, Busque L, Chan JKC, Chen W, Chen X, Chng WJ, Choi JK, Colmenero I, Coupland SE, Cross NCP, De Jong D, Elghetany MT, Takahashi E, Emile JF, Ferry J, Fogelstrand L, Fontenay M, Germing U, Gujral S, Haferlach T, Harrison C, Hodge JC, Hu S, Jansen JH, Kanagal-Shamanna R, Kantarjian HM, Kratz CP, Li XQ, Lim MS, Loeb K, Loghavi S, Marcogliese A, Meshinchi S, Michaels P, Naresh KN, Natkunam Y, Nejati R, Ott G, Padron E, Patel KP, Patkar N, Picarsic J, Platzbecker U, Roberts I, Schuh A, Sewell W, Siebert R, Tembhare P, Tyner J, Verstovsek S, Wang W, Wood B, Xiao W, Yeung C, Hochhaus A. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia. 2022 Jul;36(7):1703-1719. doi: 10.1038/s41375-022-01613-1. Epub 2022 Jun 22.
Reference Type
BACKGROUND
Proctor E, Silmere H, Raghavan R, Hovmand P, Aarons G, Bunger A, Griffey R, Hensley M. Outcomes for implementation research: conceptual distinctions, measurement challenges, and research agenda. Adm Policy Ment Health. 2011 Mar;38(2):65-76. doi: 10.1007/s10488-010-0319-7.
Reference Type
BACKGROUND
Curran GM, Bauer M, Mittman B, Pyne JM, Stetler C. Effectiveness-implementation hybrid designs: combining elements of clinical effectiveness and implementation research to enhance public health impact. Med Care. 2012 Mar;50(3):217-26. doi: 10.1097/MLR.0b013e3182408812.
Reference Type
BACKGROUND
bank, W. World Bank Country Data - Malawi. https://data.worldbank.org/country/MW (2021).
Reference Type
BACKGROUND
GBD 2017 Childhood Cancer Collaborators. The global burden of childhood and adolescent cancer in 2017: an analysis of the Global Burden of Disease Study 2017. Lancet Oncol. 2019 Sep;20(9):1211-1225. doi: 10.1016/S1470-2045(19)30339-0. Epub 2019 Jul 29.
Reference Type
BACKGROUND
Painschab MS, Westmoreland KD, Kasonkanji E, Zuze T, Kaimila B, Waswa P, El-Mallawany NK, Tomoka T, Mulenga M, Montgomery ND, Fedoriw Y, Gopal S. Prospective study of Burkitt lymphoma treatment in adolescents and adults in Malawi. Blood Adv. 2019 Feb 26;3(4):612-620. doi: 10.1182/bloodadvances.2018029199.
Reference Type
BACKGROUND
Chakumatha E, Weijers J, Banda K, Bailey S, Molyneux E, Chagaluka G, Israels T. Outcome at the end of treatment of patients with common and curable childhood cancer types in Blantyre, Malawi. Pediatr Blood Cancer. 2020 Jul;67(7):e28322. doi: 10.1002/pbc.28322. Epub 2020 May 11.
Reference Type
BACKGROUND
Kasonkanji E, Kimani S, Skiver B, Ellis G, Seguin R, Kaimila B, Tomoka T, Mulenga M, Montgomery N, Fedoriw Y, Gopal S, Westmorland KD, Painschab MS. Clinical Characteristics and Outcomes of Acute Lymphoblastic Leukemia in Adolescents and Young Adults in Malawi. JCO Glob Oncol. 2022 Jun;8:e2100388. doi: 10.1200/GO.21.00388.
Reference Type
BACKGROUND
Rubagumya F, Xu MJ, May L, Driscoll C, Uwizeye FR, Shyirambere C, Larrabee K, Fehr AE, Gilbert UD, Muhayimana C, Hategekimana V, Elmore S, Mpunga T, Moore M, Shulman LN, Lehmann L. Outcomes of Low-Intensity Treatment of Acute Lymphoblastic Leukemia at Butaro Cancer Center of Excellence in Rwanda. J Glob Oncol. 2018 Sep;4:1-11. doi: 10.1200/JGO.2017.009290. Epub 2017 Oct 30.
Reference Type
BACKGROUND
Shyirambere C, Villaverde C, Nguyen C, Ruhangaza D, Umwizerwa A, Nsanzimana O, Mujyuwisha L, Iradukunda E, Shulman LN, Lehmann L. Nephroblastoma Treatment and Outcomes in a Low-Income Setting. JCO Glob Oncol. 2022 Jul;8:e2200036. doi: 10.1200/GO.22.00036.
Reference Type
BACKGROUND
Holmes DM, Matatiyo A, Mpasa A, Huibers MHW, Manda G, Tomoka T, Mulenga M, Namazzi R, Mehta P, Zobeck M, Mzikamanda R, Chintagumpala M, Allen C, Nuchtern JG, Borgstein E, Aronson DC, Ozuah N, Nandi B, McAtee CL. Outcomes of Wilms tumor therapy in Lilongwe, Malawi, 2016-2021: Successes and ongoing research priorities. Pediatr Blood Cancer. 2023 May;70(5):e30242. doi: 10.1002/pbc.30242. Epub 2023 Feb 16.
Reference Type
BACKGROUND
Ravindranath Y, Chang M, Steuber CP, Becton D, Dahl G, Civin C, Camitta B, Carroll A, Raimondi SC, Weinstein HJ; Pediatric Oncology Group. Pediatric Oncology Group (POG) studies of acute myeloid leukemia (AML): a review of four consecutive childhood AML trials conducted between 1981 and 2000. Leukemia. 2005 Dec;19(12):2101-16. doi: 10.1038/sj.leu.2403927.
Reference Type
BACKGROUND
Hu Y, Chen A, Gao L, He H, Jiang S, Zheng X, Xiao P, Lu J, Wang Y, Li J, Li J, Fan J, Yao Y, Ling J, Fan L, Cheng S, Cheng C, Fang F, Pan J, Wang QF, Ribeiro RC, Hu S. Minimally myelosuppressive regimen for remission induction in pediatric AML: long-term results of an observational study. Blood Adv. 2021 Apr 13;5(7):1837-1847. doi: 10.1182/bloodadvances.2020003453.
Reference Type
BACKGROUND
Hu Y, Chen A, Zheng X, Lu J, He H, Yang J, Zhang Y, Sui P, Yang J, He F, Wang Y, Xiao P, Liu X, Zhou Y, Pei D, Cheng C, Ribeiro RC, Hu S, Wang QF. Ecological principle meets cancer treatment: treating children with acute myeloid leukemia with low-dose chemotherapy. Natl Sci Rev. 2019 May;6(3):469-479. doi: 10.1093/nsr/nwz006. Epub 2019 Jan 22.
Reference Type
BACKGROUND
Kapoor A, Beniwal SK, Kalwar A, Singhal MK, Nirban RK, Kumar HS. Metronomic therapy with oral 6-mercaptopurine in elderly acute myeloid leukemia: A prospective pilot study. South Asian J Cancer. 2016 Apr-Jun;5(2):70-2. doi: 10.4103/2278-330X.181644.
Reference Type
BACKGROUND
Hunger SP, Mullighan CG. Acute Lymphoblastic Leukemia in Children. N Engl J Med. 2015 Oct 15;373(16):1541-52. doi: 10.1056/NEJMra1400972. No abstract available.
Reference Type
BACKGROUND
Klein K, Haarman EG, de Haas V, Zwaan ChM, Creutzig U, Kaspers GL. Glucocorticoid-Induced Proliferation in Untreated Pediatric Acute Myeloid Leukemic Blasts. Pediatr Blood Cancer. 2016 Aug;63(8):1457-60. doi: 10.1002/pbc.26011. Epub 2016 Apr 19.
Reference Type
BACKGROUND
McAtee CL, Schneller N, Brackett J, Bernhardt MB, Schafer ES. Treatment-related sinusoidal obstruction syndrome in children with de novo acute lymphoblastic leukemia during intensification. Cancer Chemother Pharmacol. 2017 Dec;80(6):1261-1264. doi: 10.1007/s00280-017-3453-z. Epub 2017 Oct 19.
Reference Type
BACKGROUND
Bondarenko M, Le Grand M, Shaked Y, Raviv Z, Chapuisat G, Carrere C, Montero MP, Rossi M, Pasquier E, Carre M, Andre N. Metronomic Chemotherapy Modulates Clonal Interactions to Prevent Drug Resistance in Non-Small Cell Lung Cancer. Cancers (Basel). 2021 May 7;13(9):2239. doi: 10.3390/cancers13092239.
Reference Type
BACKGROUND
Cazzaniga ME, Cordani N, Capici S, Cogliati V, Riva F, Cerrito MG. Metronomic Chemotherapy. Cancers (Basel). 2021 May 6;13(9):2236. doi: 10.3390/cancers13092236.
Reference Type
BACKGROUND
Minard-Colin V, Auperin A, Pillon M, Burke GAA, Barkauskas DA, Wheatley K, Delgado RF, Alexander S, Uyttebroeck A, Bollard CM, Zsiros J, Csoka M, Kazanowska B, Chiang AK, Miles RR, Wotherspoon A, Adamson PC, Vassal G, Patte C, Gross TG; European Intergroup for Childhood Non-Hodgkin Lymphoma; Children's Oncology Group. Rituximab for High-Risk, Mature B-Cell Non-Hodgkin's Lymphoma in Children. N Engl J Med. 2020 Jun 4;382(23):2207-2219. doi: 10.1056/NEJMoa1915315.
Reference Type
BACKGROUND
van Weelderen RE, Wijnen NE, Njuguna F, Klein K, Vik TA, Olbara G, Kaspers GJL. Treatment outcomes of pediatric acute myeloid leukemia in Western Kenya before and after the implementation of the SIOP PODC treatment guideline. Cancer Rep (Hoboken). 2023 Aug;6(8):e1849. doi: 10.1002/cnr2.1849. Epub 2023 Jun 22.
Reference Type
BACKGROUND
Gallegos-Castorena S, Medina-Sanson A, Gonzalez-Ramella O, Sanchez-Zubieta F, Martinez-Avalos A. Improved treatment results in Mexican children with acute myeloid leukemia using a Medical Research Council (MRC)-acute myeloid leukemia 10 modified protocol. Leuk Lymphoma. 2009 Jul;50(7):1132-7. doi: 10.1080/10428190902964768.
Reference Type
BACKGROUND
Howard SC, Davidson A, Luna-Fineman S, Israels T, Chantada G, Lam CG, Hunger SP, Bailey S, Ribeiro RC, Arora RS, Pedrosa F, Harif M, Metzger ML. A framework to develop adapted treatment regimens to manage pediatric cancer in low- and middle-income countries: The Pediatric Oncology in Developing Countries (PODC) Committee of the International Pediatric Oncology Society (SIOP). Pediatr Blood Cancer. 2017 Dec;64 Suppl 5. doi: 10.1002/pbc.26879.
Reference Type
BACKGROUND
Parikh NS, Howard SC, Chantada G, Israels T, Khattab M, Alcasabas P, Lam CG, Faulkner L, Park JR, London WB, Matthay KK; International Society of Pediatric Oncology. SIOP-PODC adapted risk stratification and treatment guidelines: Recommendations for neuroblastoma in low- and middle-income settings. Pediatr Blood Cancer. 2015 Aug;62(8):1305-16. doi: 10.1002/pbc.25501. Epub 2015 Mar 21.
Reference Type
BACKGROUND
Bouda GC, Traore F, Couitchere L, Raquin MA, Guedenon KM, Pondy A, Moreira C, Rakotomahefa M, Harif M, Patte C. Advanced Burkitt Lymphoma in Sub-Saharan Africa Pediatric Units: Results of the Third Prospective Multicenter Study of the Groupe Franco-Africain d'Oncologie Pediatrique. J Glob Oncol. 2019 Nov;5:1-9. doi: 10.1200/JGO.19.00172.
Reference Type
BACKGROUND
Bansal D, Davidson A, Supriyadi E, Njuguna F, Ribeiro RC, Kaspers GJL. SIOP PODC adapted risk stratification and treatment guidelines: Recommendations for acute myeloid leukemia in resource-limited settings. Pediatr Blood Cancer. 2023 Nov;70(11):e28087. doi: 10.1002/pbc.28087. Epub 2019 Nov 27.
Reference Type
BACKGROUND
Israels T, Moreira C, Scanlan T, Molyneux L, Kampondeni S, Hesseling P, Heij H, Borgstein E, Vujanic G, Pritchard-Jones K, Hadley L. SIOP PODC: clinical guidelines for the management of children with Wilms tumour in a low income setting. Pediatr Blood Cancer. 2013 Jan;60(1):5-11. doi: 10.1002/pbc.24321. Epub 2012 Sep 26.
Reference Type
BACKGROUND
Espinoza D, Blanco Lopez JG, Vasquez R, Fu L, Martinez R, Rodriguez H, Navarrete M, Howard SC, Friedrich P, Valsecchi MG, Conter V, Ceppi F. How should childhood acute lymphoblastic leukemia relapses in low-income and middle-income countries be managed: The AHOPCA-ALL study group experience. Cancer. 2023 Mar 1;129(5):771-779. doi: 10.1002/cncr.34572. Epub 2022 Dec 12.
Reference Type
BACKGROUND
van Weelderen RE, Njuguna F, Klein K, Mostert S, Langat S, Vik TA, Olbara G, Kipng'etich M, Kaspers GJL. Outcomes of pediatric acute myeloid leukemia treatment in Western Kenya. Cancer Rep (Hoboken). 2022 Oct;5(10):e1576. doi: 10.1002/cnr2.1576. Epub 2021 Nov 22.
Reference Type
BACKGROUND
Kersten E, Scanlan P, Dubois SG, Matthay KK. Current treatment and outcome for childhood acute leukemia in Tanzania. Pediatr Blood Cancer. 2013 Dec;60(12):2047-53. doi: 10.1002/pbc.24576. Epub 2013 Aug 26.
Reference Type
BACKGROUND
Ngwa W, Addai BW, Adewole I, Ainsworth V, Alaro J, Alatise OI, Ali Z, Anderson BO, Anorlu R, Avery S, Barango P, Bih N, Booth CM, Brawley OW, Dangou JM, Denny L, Dent J, Elmore SNC, Elzawawy A, Gashumba D, Geel J, Graef K, Gupta S, Gueye SM, Hammad N, Hessissen L, Ilbawi AM, Kambugu J, Kozlakidis Z, Manga S, Maree L, Mohammed SI, Msadabwe S, Mutebi M, Nakaganda A, Ndlovu N, Ndoh K, Ndumbalo J, Ngoma M, Ngoma T, Ntizimira C, Rebbeck TR, Renner L, Romanoff A, Rubagumya F, Sayed S, Sud S, Simonds H, Sullivan R, Swanson W, Vanderpuye V, Wiafe B, Kerr D. Cancer in sub-Saharan Africa: a Lancet Oncology Commission. Lancet Oncol. 2022 Jun;23(6):e251-e312. doi: 10.1016/S1470-2045(21)00720-8. Epub 2022 May 9.
Reference Type
BACKGROUND
Creutzig U, Zimmermann M, Bourquin JP, Dworzak MN, Fleischhack G, Graf N, Klingebiel T, Kremens B, Lehrnbecher T, von Neuhoff C, Ritter J, Sander A, Schrauder A, von Stackelberg A, Stary J, Reinhardt D. Randomized trial comparing liposomal daunorubicin with idarubicin as induction for pediatric acute myeloid leukemia: results from Study AML-BFM 2004. Blood. 2013 Jul 4;122(1):37-43. doi: 10.1182/blood-2013-02-484097. Epub 2013 May 23.
Reference Type
BACKGROUND
Begum M, Islam A, Rahman AA, Akter M, Alam ST, Tasmeen R. Abandonment and Outcome of Childhood Acute Myeloid Leukemia in A Tertiary Level Hospital. Mymensingh Med J. 2018 Jan;27(1):95-102.
Reference Type
BACKGROUND
N, H. et al. SEER Cancer Statistics Review, 1975-2017. SEER Cancer Statistics Review, 1975-2017, National Cancer Institute.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
H-53055
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Treatment of Children and Adolescents With Refractory or Relapsed Acute Myeloid Leukemia
NCT00186966
COMPLETED
PHASE3
Phase 3 Trial for AML Patients in CR2 Comparing 8Gy TBI /Fludarabine to Conditioning With TBI 12Gy/Cyclophosphamide
NCT00125606
TERMINATED
PHASE3
A Prospective Multicenter Clinical Trial of MRD-based Treatment Strategy in Children and Young Adults With AML
NCT03846362
UNKNOWN
PHASE3
Wee1 Kinase Inhibitor AZD1775 and Combination Chemotherapy in Treating Children, Adolescents and Young Adults With Relapsed or Refractory Acute Myeloid Leukemia
NCT02791919
WITHDRAWN
PHASE1
Home Away From Home - Quality of Life Surveys
NCT02777021
COMPLETED
Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic Syndrome
NCT00002798
COMPLETED
PHASE3
Microtransplantation in Older Patients With Acute Myeloid Leukemia
NCT02831192
COMPLETED
PHASE2
Risk-Adjusted Combination Chemotherapy in Treating Young Patients With Acute Lymphoblastic Leukemia
NCT00764907
UNKNOWN
PHASE3
Hematopoietic Stem Cell Microtransplantation for in AML
NCT02676856
UNKNOWN
NA
Impact of a Pharmaceutical Care Model in the Management of Chronic Myeloid Leukemia Patients
NCT03090477
COMPLETED
NA
Transfusion in Adult Acute Myeloid Leukemia
NCT02899767
COMPLETED
AflacLL1901 (CHOA-AML)
NCT04326439
TERMINATED
PHASE2
Risk-stratified Therapy Based on Molecular Cytogenetic Aberration and Treatment Response in AML
NCT03620955
UNKNOWN
MA+AZA Regimen for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML)
NCT06345365
RECRUITING
PHASE3
Matched Targeted Therapy For High-Risk Leukemias and Myelodysplastic Syndrome
NCT02670525
ACTIVE_NOT_RECRUITING
NA
Allogenic Stem Cell Transplantation for Children, Adolescents and Young Adults With Relapsed or Refractory AML
NCT00606723
COMPLETED
PHASE3
A Prospective, Open-label, Randomized Controlled, Multicenter Clinical Study of Haplo-HSCT Using a TBI or TMLI Conditioning Regimen for Pediatric ALL
NCT06559345
RECRUITING
PHASE2
Short-term Blinatumomab as a Bridge Therapy for Allo-HSCT in Low Burden B-ALL
NCT06111625
RECRUITING
PHASE2
High Dose Donor Hematopoietic Stem Cell Infusion for Relapsed/Refractory AML
NCT03080922
UNKNOWN
PHASE1/PHASE2
Therapy-Optimization Trial for the Treatment of Acute Myeloid Leukemias (AML) in Children and Adolescents
NCT00111345
UNKNOWN
PHASE2/PHASE3
Modified Conditioning Regimen for CML-BP
NCT07259161
NOT_YET_RECRUITING
PHASE2
Total Marrow and Lymphoid Irradiation and Chemotherapy for Myelodysplastic Syndrome or Acute Leukemia
NCT03408210
UNKNOWN
NA
Lenalidomide in Treating Patients With High Risk Acute Myeloid Leukemia in Remission
NCT02126553
COMPLETED
PHASE2
Childhood Acute Lymphoblastic Leukemia Treatment Protocol Moscow-Berlin 2015 (ALL-MB 2015)
NCT03390387
RECRUITING
NA
Use of Saline-Washed Platelet and Red Cell Transfusions in Adult Acute Leukemia
NCT01976442
COMPLETED